Drug Profile
Research programme: insulin growth factor-targeted cancer therapies - Systems Medicine/NCI
Alternative Names: hmAb m610; m610Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA); Systems Medicine
- Class Monoclonal antibodies; Peptides; Small molecules
- Mechanism of Action Insulin-like growth factor I inhibitors; Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 21 Jul 2008 Preclinical development is ongoing
- 25 Oct 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the Cancer pharmacodynamics section